MESTRANOL; NORETHINDRONE - Generic Drug Details

What are the generic sources for mestranol; norethindrone and what is the scope of freedom to operate?

Mestranol; norethindrone is the generic ingredient in fourteen branded drugs marketed by Actavis Labs Ut Inc, Heritage Pharma, Watson Labs, Gd Searle Llc, Ortho Mcneil Pharm, and Ortho Mcneil Janssen, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for MESTRANOL; NORETHINDRONE

US Patents:	0
Tradenames:	14
Applicants:	6
NDAs:	11
Raw Ingredient (Bulk) Api Vendors:	5
DailyMed Link:	MESTRANOL; NORETHINDRONE at DailyMed

US Patents and Regulatory Information for MESTRANOL; NORETHINDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heritage Pharma	NORETHIN 1/50M-28	mestranol; norethindrone	TABLET;ORAL-28	071540-001	Apr 12, 1988		DISCN	No	No
Ortho Mcneil Pharm	ORTHO-NOVUM 10-21	mestranol; norethindrone	TABLET;ORAL-21	012728-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ortho Mcneil Janssen	ORTHO-NOVUM 1/50 28	mestranol; norethindrone	TABLET;ORAL-28	016709-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Heritage Pharma	NORETHIN 1/50M-21	mestranol; norethindrone	TABLET;ORAL-21	071539-001	Apr 12, 1988		DISCN	No	No
Actavis Labs Ut Inc	NORINYL 1+50 21-DAY	mestranol; norethindrone	TABLET;ORAL-21	013625-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Actavis Labs Ut Inc	NORINYL 1+50 28-DAY	mestranol; norethindrone	TABLET;ORAL-28	016659-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Mestranol and Norethindrone Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 2, 2026

Mestranol/norethindrone is an obsolete combined oral contraceptive pairing with no meaningful current U.S. branded market. Its commercial decline reflects replacement by ethinyl estradiol-based contraceptives, loss of patent exclusivity, limited manufacturer participation, and changing prescribing standards. Norethindrone remains commercially relevant as a standalone progestin and in newer combination products, but mestranol has little current market value.

What is the mestranol/norethindrone drug combination?

Mestranol/norethindrone is an oral hormonal contraceptive containing an estrogen and a progestin:

Attribute	Description
Estrogen	Mestranol
Progestin	Norethindrone
Primary use	Prevention of pregnancy
Historical brands	Norinyl, including Norinyl 1+35 and Norinyl 1+50
Dosage form	Oral tablets
Regulatory era	Primarily developed and marketed in the 1960s and 1970s
Current commercial position	Legacy or discontinued product in the U.S.
Primary replacement products	Norethindrone/ethinyl estradiol and other modern combined oral contraceptives

Mestranol is a prodrug that is converted in the body to ethinyl estradiol. Although it was widely used in early combined oral contraceptives, ethinyl estradiol became the dominant estrogen component in later products because of manufacturing, formulation, and commercial standardization advantages.

Norinyl products historically used different mestranol strengths. The principal formulations included norethindrone 1 mg combined with mestranol 35 micrograms or 50 micrograms, depending on the product presentation. Historical labeling identified the product as an oral contraceptive containing norethindrone and mestranol.[1]

What is the FDA regulatory status of mestranol/norethindrone?

The U.S. market status is effectively legacy or discontinued rather than actively competitive. The original branded products are not major current FDA-marketed contraceptive products, and mestranol/norethindrone does not have the commercial visibility of current combined oral contraceptives.

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, remains the principal source for determining whether approved abbreviated new drug applications and reference-listed drugs have active U.S. regulatory listings.[2] Historical approval does not mean that a product remains commercially marketed.

The regulatory position can be summarized as follows:

Regulatory question	Assessment
Is Norinyl a current high-volume U.S. branded product?	No
Is mestranol a mainstream ingredient in current U.S. oral contraceptives?	No
Does norethindrone remain FDA-relevant?	Yes
Are current competitors primarily generic or branded?	Both, but mainly based on newer estrogen/progestin combinations
Is there a biosimilar pathway?	No; this is a small-molecule drug
Is there an active biologic exclusivity issue?	No

Norethindrone remains active in the U.S. contraceptive market through products such as norethindrone tablets and norethindrone/ethinyl estradiol combinations. The commercial survival of norethindrone does not indicate continuing demand for the mestranol combination.

When did mestranol/norethindrone lose exclusivity?

The relevant patent protection expired decades ago. The product’s intellectual-property position is not a current barrier to generic entry.

Early oral contraceptive patents were filed in the 1950s and 1960s. Any composition, formulation, or use patents associated with first-generation mestranol/norethindrone products would generally have expired by the 1980s or 1990s, subject to the specific patent and jurisdiction. U.S. patent-term restoration did not create a meaningful modern exclusivity period for these products.

Exclusivity category	Current position
Original composition patents	Expired
Original formulation patents	Expired
Method-of-use patents	Expired or commercially irrelevant
Regulatory exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not relevant to the legacy products
Patent-term extension	No material remaining protection
Biosimilar exclusivity	Not applicable

No credible commercial case exists for relying on patent protection to defend mestranol/norethindrone pricing. Any current supply would compete on regulatory status, manufacturing economics, procurement access, and demand rather than exclusivity.

What patents protect mestranol/norethindrone today?

No active, commercially meaningful U.S. patent estate is associated with the legacy mestranol/norethindrone combination.

The relevant intellectual-property categories were:

1. The chemical entities themselves.
2. Fixed-dose oral contraceptive combinations.
3. Tablet formulations.
4. Cyclic dosing regimens.
5. Contraceptive methods using estrogen and progestin combinations.

These categories were central to the early development of oral contraceptives but are no longer barriers to generic development. Any later patents covering manufacturing processes or particular tablet compositions would not ordinarily provide practical market exclusivity for the historical product.

Are there formulation patents for mestranol/norethindrone?

No current formulation patent appears to create a meaningful market barrier. Mestranol/norethindrone is a conventional immediate-release tablet with well-established active ingredients and manufacturing methods.

A new formulation could theoretically seek patent protection for controlled release, reduced adverse effects, alternative dosing, or a novel delivery system. That would be a new product-development strategy rather than protection of the legacy Norinyl formulation. Such a product would also face clinical, regulatory, and commercial challenges because the contraceptive market already has extensive alternatives.

Are there method-of-use patents for the combination?

No active method-of-use position is commercially important for the historical indication of pregnancy prevention. Contraception is the established use, and the relevant method claims would have expired or become unenforceable through age.

How does mestranol/norethindrone compare with modern contraceptives?

Mestranol/norethindrone has been displaced by products with broader commercial support, updated labeling, more standardized supply, and greater physician familiarity.

Product class	Estrogen	Progestin	Current market position
Mestranol/norethindrone	Mestranol	Norethindrone	Legacy, limited or discontinued
Norethindrone/ethinyl estradiol	Ethinyl estradiol	Norethindrone	Established generic category
Levonorgestrel/ethinyl estradiol	Ethinyl estradiol	Levonorgestrel	Large generic and branded category
Drospirenone/ethinyl estradiol	Ethinyl estradiol	Drospirenone	Active branded and generic market
Norgestimate/ethinyl estradiol	Ethinyl estradiol	Norgestimate	Established branded and generic category
Progestin-only norethindrone	None	Norethindrone	Active category, including patients who avoid estrogen

The main competitive disadvantage is not simply age. Mestranol is no longer the standard estrogen component for most contemporary combined oral contraceptives. Prescribers and manufacturers generally work within the ethinyl estradiol and newer progestin frameworks.

Norethindrone has retained value because it is used in multiple products and has a recognized clinical role. Mestranol has not retained equivalent platform value.

What is the financial trajectory of mestranol/norethindrone?

The product’s financial trajectory is a long-term decline from historical branded revenue to negligible or unreported revenue.

Period	Financial interpretation
1960s-1970s	Commercial expansion as an early combined oral contraceptive
1980s	Mature branded product with increasing generic and newer-product competition
1990s	Erosion from patent expiry, product substitution, and newer estrogen/progestin combinations
2000s	Declining commercial relevance and reduced manufacturer focus
2010s	Limited legacy demand; no material branded growth
2020s	No identifiable material standalone revenue base in major public company reporting

No major pharmaceutical company routinely reports mestranol/norethindrone revenue as a separate financial line. The product is too old and commercially limited to support reliable public product-level sales estimates. Its current financial value is therefore best assessed through market structure rather than headline revenue.

What caused the revenue decline?

Four factors drove the decline:

1. Patent expiry removed pricing protection.
2. Generic oral contraceptives reduced the value of the original brand.
3. Ethinyl estradiol-based combinations replaced mestranol products in routine prescribing.
4. Manufacturers consolidated portfolios around higher-volume contraceptive products.

The fixed-dose tablet itself has low technical complexity. That reduces manufacturing barriers but also limits pricing power. A company reintroducing the product would face low willingness to pay, uncertain demand, limited physician preference, and competition from established generic alternatives.

Which companies are challenging mestranol/norethindrone?

There is no significant current Paragraph IV litigation campaign directed at the legacy combination. The commercial challenge has already occurred through generic substitution and therapeutic replacement.

Potential competitors are not primarily companies seeking to copy mestranol/norethindrone. They are manufacturers selling alternative contraceptive products, including:

• Generic norethindrone/ethinyl estradiol products.
• Generic levonorgestrel/ethinyl estradiol products.
• Generic norgestimate/ethinyl estradiol products.
• Generic drospirenone/ethinyl estradiol products.
• Progestin-only norethindrone products.
• Long-acting reversible contraceptives and emergency contraceptives.

Major generic contraceptive suppliers have included companies such as Teva, Viatris, Sandoz, and various contract and specialty manufacturers. Their competitive advantage is scale, portfolio breadth, wholesaler access, and established FDA-approved products, not a superior patent position around mestranol/norethindrone.

Are there Paragraph IV challenges involving mestranol/norethindrone?

No current commercially material Paragraph IV dispute is apparent for the legacy product.

Paragraph IV litigation is most relevant when an ANDA applicant challenges an unexpired Orange Book patent. Mestranol/norethindrone’s historical patents are too old to create that structure today. Any earlier generic challenges would have been resolved through the ordinary cycle of patent expiry, ANDA approval, market entry, and product substitution.

For investors and licensing teams, the practical conclusion is clear: Paragraph IV litigation is not the principal risk variable. Supply continuity, FDA listing status, manufacturing economics, and market demand are more relevant.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are low to moderate. The active ingredients are established small molecules, and the dosage form is a conventional tablet. The main barriers are commercial and operational:

• Reliable sourcing of mestranol, which has a very small modern market.
• Validated manufacturing capacity.
• Stability and content-uniformity testing.
• Quality-system maintenance for a low-volume product.
• FDA compliance and current product listing.
• Distribution economics.
• Ability to secure pharmacy, wholesaler, or institutional contracts.

Mestranol sourcing may be more difficult than norethindrone sourcing because mestranol has limited contemporary demand. A manufacturer could face minimum-order quantities, supplier concentration, or the need to qualify a specialized source. These issues can create supply risk without creating patent power.

What generic launch scenarios exist for mestranol/norethindrone?

Three scenarios are commercially plausible:

Legacy continuation

A small manufacturer continues supplying an existing market through limited distribution. This scenario requires low overhead and dependable API sourcing. It does not support premium pricing.

Regulatory reactivation

A manufacturer reactivates or acquires rights to an old product or develops an equivalent product. The regulatory pathway would be more important than patent clearance because the relevant patents have expired. Demand validation would be critical.

Market exit

The manufacturer discontinues the product because volume is insufficient to support manufacturing, pharmacovigilance, quality, and distribution costs. This is the most likely long-term direction for an obsolete mestranol-based product absent a specialized institutional or geographic demand base.

What geographic markets still matter?

The United States is not a strong growth market for mestranol/norethindrone. Commercial demand, if any, is likely to be fragmented across legacy markets, low-cost procurement channels, or jurisdictions where older oral contraceptive formulations remain recognized.

Geographic considerations include:

Region	Commercial assessment
United States	Limited legacy relevance; no meaningful patent moat
Europe	Modern contraceptive alternatives dominate
Latin America	Oral contraceptive demand remains substantial, but mestranol is not the leading growth platform
Asia-Pacific	Large contraceptive market, with strong generic competition and country-specific registration requirements
Low- and middle-income markets	Price-sensitive demand may support older products, but procurement and regulatory status determine access

International sales cannot be inferred from historical U.S. branding. Product registration, local manufacturing, tender participation, and national treatment guidelines control commercial viability.

How strong is the patent estate for mestranol/norethindrone?

The patent estate is commercially weak because it is expired, narrow in strategic relevance, and disconnected from current prescribing trends.

Patent-strength factor	Rating
Remaining composition protection	None
Remaining formulation protection	None of material commercial scope
Remaining method-of-use protection	None of material commercial scope
Freedom-to-operate risk	Low for the legacy combination
Risk of therapeutic substitution	High
Manufacturing complexity	Low to moderate
Reimbursement leverage	Low
Long-term revenue potential	Low

A new mestranol-based product could seek protection around a novel delivery system or clinical use, but that would require new development work and would not restore the historical product’s exclusivity.

Key Takeaways

• Mestranol/norethindrone is a legacy combined oral contraceptive associated historically with Norinyl.
• Mestranol has been largely displaced by ethinyl estradiol in modern contraceptive products.
• Norethindrone remains commercially active in standalone and combination medicines.
• The original patent and regulatory exclusivity periods expired decades ago.
• No meaningful current patent estate or Paragraph IV litigation protects the historical combination.
• Standalone product revenue is not separately disclosed by major pharmaceutical companies and is not expected to be material.
• The principal risks are product discontinuation, API sourcing, low volume, and therapeutic substitution.
• A generic launch would face limited IP risk but weak commercial incentives.
• The product has more relevance as a historical pharmaceutical asset than as a growth or licensing opportunity.

FAQs About Mestranol/Norethindrone

Is mestranol the same as ethinyl estradiol?

No. Mestranol is converted in the body to ethinyl estradiol, but the compounds are not identical. Mestranol was used in earlier oral contraceptives, while ethinyl estradiol became the more common estrogen component.

Is Norinyl still available in the United States?

Norinyl is not a major currently marketed U.S. contraceptive brand. Historical approval and labeling do not establish active commercial availability.

Does norethindrone still have commercial value?

Yes. Norethindrone remains important in progestin-only tablets, combined oral contraceptives with ethinyl estradiol, and other hormonal products.

Could a company patent a new mestranol contraceptive?

A new patent could potentially cover a genuinely novel formulation, delivery system, manufacturing process, or therapeutic use. The historical mestranol/norethindrone tablet itself does not provide a viable new patent position.

Is mestranol/norethindrone a biosimilar opportunity?

No. It is a conventional small-molecule drug. Any modern copy would use an ANDA or another small-molecule regulatory pathway, not the FDA biosimilar framework.

References

1. U.S. Food and Drug Administration. (n.d.). Norinyl-1+50: Norethindrone and mestranol tablet labeling. FDA archives and product labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2015). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. World Health Organization. (2022). Medical eligibility criteria for contraceptive use (5th ed., updated 2022). World Health Organization.